Severity of COVID-19 at elevated exposure to perfluorinated alkylates

• Published in: PloS one 2020-12, Vol.15 (12), p.e0244815
• Main Authors: Grandjean, Philippe, Timmermann, Clara Amalie Gade, Kruse, Marie, Nielsen, Flemming, Vinholt, Pernille Just, Boding, Lasse, Heilmann, Carsten, Mølbak, Kåre
• Format: Article
• Language: English
• Subjects: Adult; Age; Aged; Air pollution; Air pollution measurements; Alkylates; Alkylation; Biobanks; Biological Specimen Banks; Biology and Life Sciences; Chronic illnesses; Confidence intervals; Confidentiality; Coronaviruses; COVID-19; COVID-19 - blood; COVID-19 - mortality; COVID-19 - therapy; Demographic variables; Diabetes; Environmental Exposure - adverse effects; Environmental Pollutants - pharmacology; Environmental Pollutants - toxicity; Epidemiology; Exposure; Female; Fluorocarbons - pharmacokinetics; Fluorocarbons - toxicity; Health aspects; Hospitalization; Hospitals; Humans; Industrial pollution; Infections; Male; Medicine and Health Sciences; Middle Aged; Obesity; Outdoor air quality; People and Places; Perfluorochemicals; Personal identification numbers; Plasma; Population studies; Public health; Registries; Regression analysis; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Severity of Illness Index; Statistical analysis; Viral diseases
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0244815

The course of coronavirus disease 2019 (COVID-19) seems to be aggravated by air pollution, and some industrial chemicals, such as the perfluorinated alkylate substances (PFASs), are immunotoxic and may contribute to an association with disease severity. From Danish biobanks, we obtained plasma samples from 323 subjects aged 30-70 years with known SARS-CoV-2 infection. The PFAS concentrations measured at the background exposures included five PFASs known to be immunotoxic. Register data was obtained to classify disease status, other health information, and demographic variables. We used ordered logistic regression analyses to determine associations between PFAS concentrations and disease outcome. Plasma-PFAS concentrations were higher in males, in subjects with Western European background, and tended to increase with age, but were not associated with the presence of chronic disease. Of the study population, 108 (33%) had not been hospitalized, and of those hospitalized, 53 (16%) had been in intensive care or were deceased. Among the five PFASs considered, perfluorobutanoic acid (PFBA) showed an unadjusted odds ratio (OR) of 2.19 (95% confidence interval, CI, 1.39-3.46) for increasing severities of the disease. Among those hospitalized, the fully adjusted OR for getting into intensive care or expiring was 5.18 (1.29, 20.72) when based on plasma samples obtained at the time of diagnosis or up to one week before. Measures of individual exposures to immunotoxic PFASs included short-chain PFBA known to accumulate in the lungs. Elevated plasma-PFBA concentrations were associated with an increased risk of a more severe course of COVID-19. Given the low background exposure levels in this study, the role of exposure to PFASs in COVID-19 needs to be ascertained in populations with elevated exposures.